Therefore, the CD3xPDL1 BiTE may be effective in activating antitumor immunity against tumor cells that constitutively express low levels of PDL1 as well as in situations where there is already an active T cell-mediated antitumor immune response and IFNγ is driving the expression of PDL1. Here, IFNG is linked to neoplasm.